ExactCure has been acquired by Biotrial to enhance its digital twin technology for clinical trials, shifting towards a more industrial application amidst a growing medtech landscape in France.
Information on the Target
ExactCure, a pioneering medtech firm based in Nice, specializes in the development of digital twins aimed at revolutionizing medication adherence and drug safety. The company leverages individual patient characteristics—such as age, weight, renal function, and ongoing treatments—combined with computer simulations to predict the therapeutic effects of medications. Using artificial intelligence tools, ExactCure enhances therapeutic compliance and tailors treatments to meet the specific needs of patients.
Despite its innovative approach, ExactCure has faced significant challenges, including a near-collapse in September 2024. The company was subsequently placed under the stewardship of Biotrial, a French clinical trial specialist, which has provided a new direction in its strategy.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in France
The French medtech industry is characterized by its rapid growth and ongoing innovation, particularly in sectors such as digital health and artificial intelligen
Similar Deals
Siemens Healthineers → Diagnostic division of Novartis’ Advanced Accelerator Applications (AAA)
2024
Biotrial
invested in
ExactCure
in 2024
in a Merger deal